Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

ancial assistance for co-pays, co-insurance, and treatment-related travel costs.

"These significant achievements support broad access to PROVENGE, the foundation of care for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon.  "The increased capacity and positive National Coverage Decision by CMS in conjunction with the patient assistance programs will ensure patients who may benefit from treatment with PROVENGE have increased access to it."

For information about these programs, please visit www.provenge.com or call 1-877-336-3736.

PROVENGE Indication and Safety

PROVENGE was approved by the U.S. Food and Drug Administration in April 2010 as the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) reported in patients in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in patients in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion react
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
(Date:5/21/2013)... Custom Learning Designs, Inc.(CLD) unveils ... using Tin Can API combined with its own ... a leading developer of training content and solutions ... , Tin Can API is a cost-effective ... trainers more accurately measure the Return on Education ...
(Date:5/21/2013)... 21, 2013 Alpha Source, Inc., ... will be exhibiting for the 13th consecutive year ... Instrumentation (AAMI) 2013 Conference and Expo. The conference ... and manufacture healthcare technologies. This year’s event will ... California. , The three-day event draws over ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3
... Israel, May 15 Modigene Inc. (OTC,Bulletin Board: ... develop longer-acting versions of already approved,therapeutic proteins, today ... upcoming Acumen BioFin Rodman & Renshaw 5th Annual ... Central European Summer Time),on May 20, 2008., ...
... LAUREL, N.J., May 15 MedQuist Inc.,(Pink ... documentation,workflow technology and services, and StructuRad LLC, ... they have agreed to,integrate and use StructuRad,s ... Radiology(TM) speech recognition solution product., MedQuist ...
... today announced,that researchers will present eight abstracts ... Meeting of the American Thoracic Society, from ... Presentations are designed to showcase,MedImmune,s biologics capabilities., ... solutions that may one,day help patients struggling ...
Cached Biology Technology:MedQuist and StructuRad Form Partnership to Integrate Report Macros into SpeechQ for Radiology(TM) 2Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 2
(Date:5/21/2013)... that the nation,s land and water resources could likely ... to 25 billion gallons of algae-based fuel a year ... needs. , The findings come from an in-depth look ... grow significant amounts of algae in large, specially built ... 7 issue of Environmental Science and Technology , ...
(Date:5/21/2013)... Water Center today awarded 12 research grants, totaling ... protection efforts. , The two-year grants of up ... to track the remediation of harmful algae blooms; ... weedy plant invasions; study chromosomal damage in tree ... activities. , The grants were awarded to multidisciplinary ...
(Date:5/21/2013)... MA -- Over the past few decades, scientists have ... angioplasty balloons and metallic stents. While generally effective, each ... side effects. , A new study from MIT analyzes ... the benefits of angioplasty balloons and drug-releasing stents, but ... balloon is inflated in the artery for only a ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
... the ESA,s Herschel far-infrared space observatory - the latest ... and galaxies - will be completed. , ESA and ... conference in Friedrichshafen, Germany, on 19 September 2007, to ... to view the very heart of its hardware. , ...
... paracetamol is used to soothe every kind of pain, from ... medicine is one of the most used nowadays. However, research ... the University of Granada showed that taking paracetamol ... vitro studies. Author of this work is Olga Garca ...
... InfoExchange(TM) Software Access Local ... Information Anytime and Anywhere, ... Bulletin Board: BKYI), a leader in wireless public safety,solutions ... its InfoExchange Software Module and its acceptance by several,agencies ...
Cached Biology News:Paracetamol, one of most used analgesics, could slow down bone growth 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 3
... UV irradiation and antimicrobial stainless steel to ... Quickly inactivate DNA between experiments with ... with antimicrobial coated stainless steel ... built-in 30-minute timer UVP's Sterilizing ...
... The flexible and easy to ... to control all members of ... It features a clear and ... assay setup, user-friendly and highly ...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Biology Products: